PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

PhaseBio Pharmaceuticals (NASDAQ: PHAS) announced that CEO Jonathan P. Mow will participate in Cowen's 42nd Annual Health Care Conference on March 8, 2022, from 12:50 PM to 1:50 PM ET. The event is virtual, and interested individuals can access the live and archived webcasts on the company's website. PhaseBio focuses on developing therapies for cardiovascular conditions, with key products in its pipeline including bentracimab, pemziviptadil, and PB6440. For more details, visit www.phasebio.com.

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42^nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET.

Interested parties can access the live and archived webcasts of the virtual session on the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.

About PhaseBio

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. PhaseBio’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly VIP receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com, and follow us on Twitter @PhaseBio and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220224006067/en/

PhaseBio Investor Contact:

John Sharp

Chief Financial Officer

(610) 981-6506

john.sharp@phasebio.com

PhaseBio Media Contact:

Will Zasadny

Canale Communications, Inc.

(619) 961-8848

will.zasadny@canalecomm.com

Source: PhaseBio Pharmaceuticals, Inc.

FAQ

What will Jonathan P. Mow discuss at Cowen's 42nd Annual Health Care Conference?

Jonathan P. Mow will participate in a panel discussion at Cowen's 42nd Annual Health Care Conference on March 8, 2022.

How can I access the webcast of PhaseBio's presentation?

You can access the live and archived webcasts of PhaseBio's presentation on their website under the 'Events and Presentations' section.

What products does PhaseBio Pharmaceuticals have in its pipeline?

PhaseBio's pipeline includes bentracimab, pemziviptadil, and PB6440, targeting cardiovascular and cardiopulmonary diseases.

When is the Cowen Health Care Conference taking place?

The Cowen Health Care Conference is scheduled for March 8, 2022, from 12:50 PM to 1:50 PM ET.

What is the focus of PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals focuses on developing novel therapies for cardiovascular diseases.